A stabilized synthetic analog of growth-hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl group, supplied as 10 mg sterile lyophilized powder for in-vitro endocrinology research.
$89.9544 in stock
For laboratory and research use only. Not for human consumption.
This product is not a drug, food or cosmetic. It is sold exclusively to qualified researchers and licensed laboratories.
44 in stock
Tested by Freedom Diagnostics TestingHPLC purity + LC-MS identityLot-matched COA on-site
US-synthesizedMade & lab-released in the United States
Independent COAThird-party Certificate of Analysis per lot
HPLC + LC-MSPurity by HPLC, identity by mass spectrometry
Same-day dispatchOrders before 2 PM CT ship the same business day
What is Tesamorelin?
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH 1-44). An N-terminal trans-3-hexenoyl modification protects the peptide from dipeptidyl-peptidase cleavage, giving it markedly greater stability than native GHRH(1-44). It binds the GHRH receptor on pituitary somatotrophs and stimulates the synthesis and pulsatile release of endogenous growth hormone, which is what makes it the reference long-acting GHRH analog in endocrinology research.
Research areas where laboratories buy tesamorelin for in vitro work include GHRH-receptor binding and cAMP-accumulation assays in receptor-expressing cells, somatotroph growth-hormone-release and downstream IGF-1 studies in cell-culture and rodent models, enzymatic-stability comparisons against native GHRH(1-44) and GHRH(1-29), GH-axis pulsatility modeling, and structure-activity studies of N-terminally protected GHRH analogs.
Every lot, independently verified
Independently third-party tested and matched to the lot ID printed on your vial. Values below are from the latest released lot.
Every lot is released against Koi's full QC panel — HPLC purity, LC-MS identity, net content, heavy metals, sterility, and endotoxin — by an independent third-party laboratory (Freedom Diagnostics Testing). Values shown are from the latest released lot and vary batch to batch; per-test results are recorded in each lot's release documentation and matched to the lot ID printed on the vial.
Browse full COA library →
Compound information
Chemical & structural reference data — specifications, molecular profile and handling.
Product Specifications
CompoundTesamorelin (stabilized GHRH 1-44 analog)
Vial size10 mg
Purity≥99% by HPLC
Identity confirmationMass spectrometry
FormLyophilized white to off-white powder
Appearance in solutionClear, colorless solution
ManufacturingSynthesized and lyophilized in the United States
Structure classStabilized 44-amino-acid GHRH analog; N-terminal trans-3-hexenoyl group confers resistance to dipeptidyl-peptidase cleavage
Storage & Handling
AppearanceWhite lyophilized powder
SolubilitySterile water or buffer · neutral pH
Storage · powder−20 °C, desiccated, dark (−80 °C long-term)
In solution2–8 °C; aliquot & freeze, avoid freeze-thaw
Tesamorelin Mechanism of Action
Binds the GHRH receptor (GHRH-R) on pituitary somatotrophs, stimulating growth-hormone synthesis and release.
Signals through Gαs / adenylyl-cyclase / cAMP, raising intracellular cAMP and GH gene transcription.
The N-terminal trans-3-hexenoyl modification confers resistance to dipeptidyl-peptidase cleavage, extending stability relative to native GHRH(1-44).
Drives downstream IGF-1 production via the GH axis in physiological models.
Preserves pulsatile GH release in physiological models.
Studied as the reference long-acting GHRH analog in endocrinology research.
Tesamorelin Research Applications
GHRH-R binding and cAMP-accumulation assays in receptor-expressing cells, where tesamorelin serves as the reference long-acting GHRH analog.
Somatotroph GH-release and downstream IGF-1 studies in cell-culture and rodent models.
Enzymatic-stability comparisons against native GHRH(1-44) and GHRH(1-29).
GH-axis pulsatility modeling under defined conditions.
Structure-activity studies of N-terminally protected GHRH analogs.
Comparative secretagogue-synergy experiments with GHRP agonists.
Why Buy Tesamorelin from Koi Peptides?
Every batch of Koi tesamorelin is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing.
Each lot is tested by HPLC for purity, LC-MS for identity confirmation, and screened for endotoxin before release.
The lot ID is printed on every vial and ties back to a public COA library, so researchers can verify documentation before they buy and after the vial arrives.
Orders placed before 2 PM CT ship the same business day, and shipping is free on orders over $200.
References
The laboratory and preclinical research behind Tesamorelin — cited for scientific context.
Mayo, K. E., et al. (1995). Growth hormone-releasing hormone and its receptor. Endocrine Reviews, 16(1), 1–32. doi.org/10.1210/edrv-16-1-1
Ferdinandi, E. S., et al. (2007). Non-clinical pharmacology and safety evaluation of TH9507, a stabilized analog of GHRH. J. Clinical Endocrinology & Metabolism.
Guillemin, R., et al. (1982). Growth hormone-releasing factor from a human pancreatic islet tumor. Science, 218(4572), 585–587. doi.org/10.1126/science.6812220
Regulatory Status
Regulatory status — provided for research context.
Research Use
The tesamorelin supplied by Koi Peptides is a research-grade reagent synthesized for laboratory research only. It is not formulated, packaged or labeled as a drug, food or cosmetic, and is not authorized for any human or veterinary use.
Disclaimer
For laboratory and research use only. Not for human consumption. This product is not a drug, food or cosmetic. It is sold exclusively to qualified researchers and licensed laboratories. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Tesamorelin is the reference stabilized GHRH(1-44) analog for studying GHRH-receptor signaling, growth-hormone release, and downstream IGF-1 dynamics. In vitro studies use it in GHRH-R binding and cAMP-accumulation assays, somatotroph GH-release models, enzymatic-stability comparisons against native GHRH, and GH-axis pulsatility modeling.
What purity is Koi's tesamorelin?+
Koi tesamorelin is ≥99% pure by HPLC (latest released lot 99.06%), with identity confirmed by LC-MS. Every lot is released against independent third-party laboratory (Freedom Diagnostics Testing) testing covering HPLC purity, LC-MS identity, net content, heavy metals, sterility, and endotoxin, and the COA is published against the lot number printed on the vial.
How do I prepare a tesamorelin solution?+
Dissolve in sterile water or a suitable buffer at neutral pH. Add diluent slowly down the vial wall rather than onto the cake, and avoid vortexing. Prepare working dilutions immediately before use, and for sterile cell-culture work filter through a 0.22 µm low-protein-binding filter. Store prepared solutions at 2 to 8 °C, or aliquot and freeze at −20 °C or below.
What is the CAS number for tesamorelin?+
The CAS number for tesamorelin is 218949-48-5. It is the N-terminal trans-3-hexenoyl GHRH(1-44) analog, with molecular formula C221H366N72O67S and a molecular weight of 5135.90 g/mol.
Is tesamorelin for human use?+
No. Tesamorelin is for laboratory and research use only and is not for human consumption. It is sold exclusively to qualified researchers and licensed laboratories.
How should tesamorelin be stored?+
Store the lyophilized powder at −20 °C, desiccated and protected from light; for long-term storage −80 °C is preferred. Minimize handling time outside the freezer. Once dissolved, store at 2 to 8 °C or aliquot and freeze. Avoid repeated freeze-thaw cycles.
Stock your lab with Koi
Research-grade peptides — made in the USA, third-party tested, with public lot-matched COAs. Shop the catalog, or contact our team with questions.
